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Abstract
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in
infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein.
MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased
histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133
(Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found
on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell
growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element
(KEE) leading to increased enhancer–promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus
regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells,
the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of
TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis
of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.
Introduction
CD133, encoded by the PROM1 gene, is a pentaspan trans-
membrane glycoprotein of great potential value as a pan-
cancer target as it is commonly associated with cancer stem
cells in multiple different tumor types, including leukemia
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[1, 2]. Proof-of-principle studies have shown that targeting
CD133 can be used to deliver nanoparticles to gastric stem
cells [3], or for chimeric antigen receptor T cell therapy in
acute lymphoblastic leukemias (ALL) caused by rearrange-
ments of the Mixed Lineage Leukemia (MLL) gene [4].
Despite vast improvements in treatment for ALL, MLL
gene rearrangements (MLLr) still cause very poor prognosis
ALLs especially in infants [5–9]. The most common MLL
rearrangement is the t(4;11) (q21;q23) chromosome translo-
cation that fuses MLL in frame with the AF4 gene producing
MLL-AF4 and AF4-MLL fusion proteins [7, 10–12]. MLL-
AF4 and other MLL fusion proteins (MLL-FPs) bind to gene
targets and cause inappropriate gene activation through
multiple transcription elongation and epigenetic mechanisms
[13], including recruitment of the histone H3 lysine-79
(H3K79) methyltransferase DOT1L [7, 14–17]. In addition to
a role in transcription elongation, recent work from our lab
has shown that H3K79me2/3 has an important role at a subset
of enhancers (H3K79me2/3-marked enhancer elements
(KEEs)), increasing expression of key gene targets through
the maintenance of enhancer–promoter interactions [18].
One of the most attractive features of PROM1/CD133 as
a potential therapeutic target derives from the recognition
that the gene is a direct target of MLL-AF4 regulation
[17, 19, 20], suggesting that in MLLr leukemias PROM1/
CD133 expression is tightly linked to the activity of the
fusion protein itself. However, the exact details of how this
locus is regulated by MLL-AF4 is unclear, and whether and
how PROM1/CD133 contributes to MLLr leukemic growth
is unknown. Understanding these mechanisms is likely to
be key to the future development of PROM1/CD133-
directed therapeutic targeting in these leukemias.
To better understand the role of PROM1/CD133 in MLLr
leukemias, we have systematically characterized the struc-
ture of the PROM1 gene locus and the mechanism of
PROM1/CD133 regulation for the first time. Importantly,
we show that two CD133-expressing MLL-AF4 cell lines
(SEM and RS4;11) are addicted to its continued expression.
Using a high-resolution chromosome conformation capture
technique (next generation Capture-C [21]) to analyze the
enhancer–promoter structure of the PROM1/CD133 locus,
we find that PROM1 expression is activated by a series of
intragenic KEEs within PROM1 as well as in the nearby
TAPT1 gene. As with other well-characterized KEEs [18],
we demonstrate that MLL-AF4 aberrantly upregulates
PROM1 transcription by controlling enhancer–promoter
interactions via increased H3K79 methylation and H3K27
acetylation. In contrast, we find that in CD133-negative
leukemia cells the PROM1 promoter is bound by compo-
nents of the polycomb repressive complex 2 (PRC2) and
this is associated with a lack of enhancer features, including
enhancer–promoter interactions. Overall, our results show
that PROM1/CD133 expression is directly upregulated by
the presence of MLL-AF4 through H3K79me2/3-mediated
enhancer–promoter interactions, and that PROM1 expres-
sion contributes to the leukemic growth of CD133+ cells.
These results for the first time elucidate the mechanism of
PROM1/CD133 upregulation and provide an explanation
for the widespread expression of CD133 in MLLr ALLs. It
also provides an interesting paradigm illustrating how
repression of a single locus (PROM1) can impact regulation
of a nearby locus (TAPT1) by suppressing access to key
enhancer sequences.
Materials and methods
Cell culture and cell lines
SEM (MLL-AF4 B-ALL line [22]), ML-2 (MLL-AF6 AML
line [23]), SHI-1 (MLL-AF6 AML line [24]), and RCH-
ACV (E2A-PBX1 cALL line [25]) cells were purchased
from DMSZ (www.cell-lines.de) and cultured in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with
10% fetal calf serum (FCS, Gibco) and Glutamax (Ther-
moFisher Scientific). RS4;11 (MLL-AF4 B-ALL line),
THP1 (MLL-AF9 AML line), MV4;11 (MLL-AF4 AML
line), and CCRF-CEM (T-ALL line) cells were purchased
from ATCC (www.lgcstandards-atcc.org). RS4;11, THP1,
and CCRF-CEM were cultured using RPMI with 10% FCS
and Glutamax. MV4;11 cells were cultured as per the SEM
conditions. All cell lines were confirmed free from myco-
plasma contamination.
Cell culture drug treatment
Cells were treated with EPZ-5676 as previously described
[17, 18]. Briefly, SEM and RS4;11 cells were treated with 2
µM EPZ-5676 or dimethyl sulphoxide (control). Cells were
treated for 7 days with media and EPZ-5676 changed on
days 3 and 6 and diluted to 0.5 × 106 cells/ml and 0.8 × 106
cells/ml, respectively. Cells were collected on day 7 and
processed for downstream applications. Cells were treated
for 5 days with UNC1999 at 5 µM and GSK126 at 2 µM,
with cells split and fresh media and inhibitor added on day
3. Venetoclax was used at 0.5 µM for 24 h, and camp-
tothecin was used at 1 µM for 1 h.
Primograft
For details of sample preparation see Ref. [17].
Patient samples
Infant and pediatric ALL samples were obtained from
patients being treated at Great Ormond Street Hospital for
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Children, London after informed consent, and analyzed as
part of their diagnostic workup. Additional MLLr ALL
samples were obtained from Bloodwise Childhood Leu-
kaemia Cell Bank, UK (REC: 16/SW/0219). All ALL
samples were anonymised at source, assigned a unique
study number and linked. Donated fetal tissue was provided
by the Human Developmental Biology Resource (www.
hdbr.org, covered under REC: 08/H0906/21+5) regulated
by the UK Human Tissue Authority (www.hta.gov.uk).
Second-trimester fetal bone marrow (BM) and liver was
processed as previously described [26]. CD34+ and
CD34− populations were isolated using magnetic beads
(Miltenyi).
Flow cytometry analysis
Cells were stained with fluorophore-conjugated monoclonal
antibodies in PBS with 2% FBS and 1 mM EDTA for 30
min and analyzed using BD LSR II or Fortessa X50
instruments. For viability eBioscience Fixable Viability Dye
eFluor 506 (ThermoFisher Scientific) or Hoechst 33342
(ThermoFisher Scientific) was used. Annexin V binding
was assayed using the eBioscience Annexin V Apoptosis
Detection Kit APC (ThermoFisher Scientific). Antibodies
used are detailed in Supplementary Table 1. Analysis was
performed using FlowJo software with gates set using
unstained and fluorescence-minus-one controls.
siRNA knockdown
siRNA knockdowns were performed in SEM and
RS4;11 cells as described [17]. For PROM1 KD, Ambion
Silencer select siRNAs (ThermoFisher Scientific) were
used: siRNA 1: s16879; siRNA 2: s16879; NT: Silencer
Negative Control No. 2. For MLL-AF4 KD, NT siRNA:
sense AAAAGCUGACCUUCUCCAAUG; antisense
CAUUGGAGAAGGUCAGCUUUUCU. MLL-AF4 KD
siRNA: sense AAGAAAAGCAGACCUACUCCA; anti-
sense UGGAGUAGGUCUGCUUUUCUUUU.
SEM PROM1/CD133 shRNA lines
shRNA sequences, which were designed using the siRNA
targeting sequences, were cloned into a doxycycline-
inducible shRNA vector (miRE_18_LT3GEPIR) using the








AAGGGGCTAG. SEM cells were lentivirally transduced
with either shRNA plasmid and clonal lines were estab-
lished using 0.5 µg/ml puromycin.
Colony-forming assay
Wild-type or PROM1 shRNA SEM cell lines were treated
with 0.5 µg/ml doxycycline 24 h prior to colony assay
plating. Five hundred doxycycline-treated or -untreated
cells were plated in IMDM MethoCult media with 20%
FCS (H4100; STEMCELL Technologies) per dish, in tri-
plicate, with 0.5 µg/ml doxycycline added to the media
where appropriate. Colonies were incubated for 14–16 days
(37 °C, 5% CO2) and then counted. For replating, after
counting cells were washed in IMDM, and 500 cells were
added to fresh IMDM MethoCult media, with doxycycline
added where appropriate, and plated for 14 days.
Cell cycle analysis
1 × 106 cells were fixed in 70% ethanol and incubated at 4 °
C overnight, then stained with FxCycle PI/RNase staining
solution (ThermoFisher Scientific). Cells were analyzed
using 532 nm excitation and collected using 585/42 band-
pass. Analysis was performed using FlowJo software.
Immunofluorescence
Cells were prepared for imaging by attachment to coverslips
coated with 0.01% Poly-L-Lysine and fixed for 15 min with
4% PFA. Cells were incubated with anti-γH2AX primary
antibody (Cell Signaling Technology 9178) for 1 h at room
temperature. Cells were then washed with PBS and incu-
bated with secondary antibody for 30 min at room tem-
perature. Cells were washed with PBS and mounted onto
slides using Vectashield with DAPI. Images were acquired
at room temperature using a Zeiss AXIO Observer.Z1
inverted microscope equipped with a Zeiss LSM‐880 con-
focal system using a Plan-Apochromat 63x/1.4 Oil DIC
M27 objective. Images were then processed using OMERO
(v5.4.9).
Western blotting
Salt-soluble protein and histone extraction from 1 × 106
SEM cells was conducted as previously described [18],
followed by western blotting [27]. Antibodies used are
detailed in Supplementary Table 1.
qRT-PCR
For qPCR applications, RNA was extracted from 1 × 106
cells using the RNeasy Mini Kit (Qiagen). RNA was reverse
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transcribed using Superscript III (ThermoFisher Scientific)
with random hexamer primers (ThermoFisher Scientific).
Samples were analyzed by Taqman qPCR, using the
housekeeping gene YWHAZ for gene expression normal-
ization. For list of qPCR primers used see Supplementary
Table 2.
Poly(A) RNA purification and sequencing
RNA was extracted from 1 × 107 PROM1 shRNA 1 SEM
cells lines using the Directzol RNA MiniPrep Kit (Zymo
R2050). Poly(A) purification was conducted using the NEB
Poly(A) mRNA magnetic isolation module following the
manufacturer’s protocol. Library preparation was carried
out using the Ultra II Directional RNA Library Prep Kit
(NEB, E7765). RNA libraries were sequenced by paired-
end sequencing using a 150 cycle high output kit on a
Nextseq 500 (Illumina).
Gene expression analysis
Following sequencing, QC analysis was conducted using
the fastQC package (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc). Reads were mapped to the human
genome assembly hg19 using STAR [28]. PCR duplicates
were removed from the mapped reads using Samtools [29].
The featureCounts function from the Subread package was
used to quantify gene expression levels using standard
parameters. This was used to identify differential gene
expression globally, generating RPKM values, using the
edgeR package [30]. Differential gene expression was
defined by an adjusted p value (FDR) of <0.05. Infant ALL
[31–33] and normal BM [34–36] RNA-seq datasets were
analyzed as described previously [36].
Single-cell gene expression analysis
Single-cell data was analyzed using the Seurat package [37]
following standard methods. Briefly, a random subset of 105
cells were chosen for analysis. Cells were initially filtered
removing those that contained less than 200 and more than
2500 genes. Cells with >5% mitochondrial genes were
removed. Genes detected in less than four cells were
removed. Data were normalized using the log normalize
method with a scale factor of 10,000. FindVariableFeatures,
RunPCA, and RunTSNE were used for dimension reduc-
tion. FindNeighbours and FindCluster functions were used
to find cell clusters. FindAllMarkers was used to marker
genes of each cluster and cell types were identified using
published marker signatures [38] and a custom gene voting
system. Cell clusters and gene expression were visualized
using DimPlot and FeatureScatter functions.
ChIP-qPCR and ChIP-seq
The full protocol is described in [17, 18]. Briefly, 107–108
cells were sonicated (Covaris) following the manufacturer’s
protocol. Magnetic protein A and G beads (ThermoFisher
Scientific) were used to isolate antibody-chromatin com-
plexes. Antibodies used are detailed in Supplementary
Table 1. Beads were washed three times using a solution of
50 mM HEPES-KOH (pH 7.6), 500 mM LiCl, 1 mM
EDTA, 1% NP40 and 0.7% sodium deoxycholate, and once
with Tris-EDTA. Samples were eluted and Proteinase
K/RNase A-treated. Samples were purified using the Qiagen
PCR purification kit. DNA content was analyzed by qPCR
or ChIP-sequencing. For list of qPCR primers used see
Supplementary Table 2. For ChIP-seq, DNA libraries were
generated using the NEBnext Ultra DNA library preparation
kit for Illumina (NEB). Libraries were sequenced by paired-
end sequencing using a 75 cycle high output kit on a
Nextseq 500 (Illumina).
ATAC-seq
ATAC-seq was performed using the Nextera Tn5 transpo-
sase (Illumina) on 6 × 104 THP1 cells and whole BM from
an MLL-AF4 ALL pediatric patient, as previously descri-
bed [18, 39]. Libraries were sequenced by paired-end
sequencing using a 75 cycle high output kit on a Nextseq
500 (Illumina).
Sequence analysis
For ChIP-seq and ATAC-seq, quality control of FASTQ
reads, alignment, PCR duplicate filtering, blacklisted region
filtering, and UCSC data hub generation was performed
using an in-house pipeline (https://github.com/Hughes-
Genome-Group/NGseqBasic/releases) as described [18].
The Homer tool makeBigWig.pl command was used to
generate bigwig files for visualization in UCSC, normal-
izing tag counts to tags per ten million. Gene profiles were
generated using annotatePeaks.pl.
Capture-C
For details on Capture-C methods used see Refs. [18, 21].
Biotinylated oligo probes, with the following sequences,

















Data analysis was performed using an in-house pipeline
(https://github.com/Hughes-Genome-Group/CCseqBasicF/
releases; Davies 2016) and statistical analysis was per-
formed as described [18].
Statistical analysis
Statistical analyses used and sample sizes are indicated in
figure legends; n numbers refer to independent experiments
(for cell lines) or biological samples (for patient data). All
tests were conducted two-tailed. Samples were only exclu-
ded from analysis if positive and negative controls did not
give the expected results.
Results
MLLr leukemia cell lines and primary ALL blasts
show heterogeneous expression of PROM1/CD133
In order to model PROM1/CD133 behavior and regulation,
we first evaluated CD133 expression by flow cytometry to
identify CD133-positive and -negative leukemia cell lines
(Fig. 1a). As also observed by others [4], while two MLL-
AF4 ALL cell lines (SEM and RS4;11) displayed high
levels of CD133 expression, CD133 was undetectable on
the surface of THP1 (MLL-AF9 AML), MV4;11 (MLL-
AF4 AML), and RCH-ACV (non-MLLr ALL) cells
(Fig. 1a). This was confirmed at the RNA level by qRT-
PCR (Supplementary Fig. 1a). Interestingly, PROM1
demonstrated a similar expression pattern to the neighbor-
ing gene TAPT1 (Supplementary Fig. 1a, b). Although
TAPT1 is expressed even when PROM1 is not (albeit at
lower levels), higher PROM1 expression correlated with
higher TAPT1 expression in the cell lines analyzed (Sup-
plementary Fig. 1a). We observed a similar correlation of
expression in a published dataset [32] of leukemia patient
samples (Supplementary Fig. 1c, R2= 0.4251), confirming
this phenomenon is not restricted to cell lines and sug-
gesting the genes may be co-regulated in leukemia. Cell
surface expression of CD133 does not cause upregulation of
TAPT1, as transfection of CD133-negative THP1 cells with
a PROM1 expression plasmid did not result in an increase in
TAPT1 expression (Supplementary Fig. 1d). This suggests
that it is the active transcription of the PROM1 locus itself
that may contribute to the upregulation of TAPT1.
To determine if heterogeneity in CD133 expression was
observed in ALL patient samples, we analyzed 44 primary
precursor B-ALL samples: 12 MLLr and 32 non-MLLr
(sorting strategy shown in Supplementary Fig. 1e).
Although there was a wide range of CD133 expression
(measured by the proportion of blasts with detectable
CD133) in both MLLr and non-MLLr ALL, mean and
median levels of CD133 expression were markedly higher in
MLLr cases (Fig. 1b, p < 0.0001, mean 64.9% ± 10.2 s.e.m.
vs. 15.7% ± 4.2 s.e.m., median 74.9% vs. 2.5% for MLLr
and non-MLLr blasts, respectively; Supplementary Fig. 1f),
and a significantly greater number of MLLr ALL samples
(9/12) expressed CD133 on the majority of cells (>50%)
compared with 4/32 non-MLLr ALL. To correlate this with
gene expression patterns, we analyzed RNA-seq data from
published datasets of large cohorts of infant and childhood
ALL patient blasts [32, 33]. In keeping with previous
findings [40], MLLr leukemia cells were found to
express PROM1 at much higher levels than the non-MLLr
cohort (Fig. 1c).
To test whether the specific MLL fusion partner con-
tributes to PROM1 expression status we analyzed two ALL
datasets for which fusion partner status was available
[31, 32]. Strikingly, whilst MLL-AF4 and MLL-ENL ALL
samples displayed high levels of PROM1 expression, other
fusion proteins, including MLL-AF9, were associated with
lower levels of expression, more comparable to non-MLLr
leukemias (Supplementary Fig. 1g). Taken together, these
data indicate that although a CD133+ immunophenotype is
not restricted to MLLr ALL, PROM1/CD133 is aberrantly
expressed in a large subset of cell lines and MLLr leukemia
patients, particularly those associated with MLL-AF4 and
MLL-ENL fusion proteins.
CD133 is important for MLL-AF4 ALL
leukemogenesis
To test whether CD133 is important for MLL-AF4 leuke-
mia growth we generated two SEM cell lines containing
different doxycycline-inducible shRNA sequences targeting
PROM1. Levels of PROM1 RNA were significantly
reduced 48 h after induction (Fig. 1d). To test whether
PROM1 is important for leukemogenesis we performed
colony-forming assays on cells after 24 h doxycycline
treatment. A reduction in CD133 expression prior to colony
assay (day 1) was verified by flow cytometry (Fig. 1e and
Supplementary Fig. 1h), and levels were further decreased
in the cells post-colony assay (day 17). We observed a
striking reduction in colony-forming ability following
PROM1 knockdown using either shRNA, and not with
doxycycline-treated control SEM cells, with the number of
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colonies reduced to <50% of the uninduced control
(Fig. 1f). This effect was reproducible following two rounds
of serial replating of colonies (Supplementary Fig. 1i).
Thus, CD133 is clearly an important protein for the leu-
kemic potential of SEM cells.
The inability of PROM1 KD SEM cells to form colonies
was matched by a dramatically reduced growth rate in
liquid culture (Fig. 1g). We confirmed this in another MLL-
AF4 CD133+ cell line, RS4;11 (Fig. 1a), where siRNA-
mediated knockdown of PROM1 (Supplementary Fig. 2a)
had a similarly dramatic effect on cell growth (Supple-
mentary Fig. 2b). The loss of cell growth following PROM1
KD may be explained by a reduced growth rate and/or
increased apoptosis. We tested the former possibility by
performing cell cycle analysis of SEM cells after shRNA
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revealed a shift in cell cycle status following PROM1
depletion, with an increase in the proportion of cells in G1
phase and a decrease in S phase, suggesting a delay in
transition between the stages (Fig. 1h and Supplementary
Fig. 2c). We tested for apoptosis by Annexin V staining
(Supplementary Fig. 2d) and western blot for cleaved PARP
(Supplementary Fig. 2e), a known caspase 3 substrate.
These demonstrated an increase in apoptosis following
PROM1 shRNA induction, but not doxycycline treatment of
control SEM cells (Supplementary Fig. 2d, e). Taken
together, these data suggest that PROM1 is likely involved
in promoting both cell growth and survival.
To further investigate the dependence of SEM cells on
CD133 expression, we performed RNA sequencing in the
PROM1 shRNA cell line. Differential gene expression
analysis revealed 865 up- and 1147 down-regulated genes
72 h after PROM1 shRNA induction (Fig. 1i). Consistent
with the disrupted cell cycle of these cells, the
downregulated genes were enriched for genes involved in
the cell cycle and other processes associated with dereg-
ulation of the cell cycle, including DNA replication
(Fig. 1j). We also observed downregulation of DNA
repair genes, including genes involved in the Fanconi
anemia pathway and mismatch repair (Fig. 1j), which
may be a consequence of the reduced S phase (Fig. 1h) as
these processes are associated with DNA replication.
This was not associated with an increase in double-strand
breaks, as measured by γH2AX levels (Supplementary
Fig. 2f, g).
MLL-AF4 directly binds to and regulates PROM1
expression
To understand how PROM1 expression is regulated in
CD133+ MLLr leukemias, we analyzed ChIP-seq datasets
from multiple cell types, using MLL-N and AF4-C binding
as a proxy for MLL-AF4 fusion protein binding. In line
with previous findings [17, 20, 27, 41], we identified MLL-
AF4 binding at the promoter and spreading into the gene
body of PROM1 in CD133+ ALL cell lines (SEM and
RS4;11; see Fig. 1a) and in MLL-AF4 blasts from a CD133
+ ALL patient primograft [17] (Fig. 2a and Supplementary
Fig. 3a). Published FLAG-MLL-Af4 ChIP-seq from MLL-
Af4-transformed CD34+ cord blood cells [20] revealed a
similar binding distribution at the PROM1 locus (Fig. 2a,
bottom panel). Notably, in all four cell types the neigh-
boring TAPT1 gene was also marked by a broad domain of
MLL-AF4 binding (Fig. 2a). H3K79me2/3, a histone
modification found at high levels at MLL-FP gene targets
[16, 17], was observed to colocalize with MLL-AF4 at
PROM1 in SEM, RS4;11, and the MLL-AF4 ALL primo-
graft cells, further validating the gene as a bona fide MLL-
AF4 target (Fig. 2b).
Binding of MLL-AF4 to PROM1 suggests that it may
directly regulate PROM1 transcription. To test this, we
interrogated nascent RNA-seq data from SEM cells fol-
lowing siRNA-mediated knockdown of MLL-AF4 [17, 18],
which produced clear reductions in MLL-N and AF4-C
binding across PROM1 and TAPT1, as well as a known
MLL-AF4 gene target, BCL11A (Fig. 2c) [17, 18]. We
observed a dramatic reduction in PROM1 transcription
following MLL-AF4 knockdown (p < 0.001, Fig. 2d and
Supplementary Fig. 3b), confirmed by qRT-PCR (Supple-
mentary Fig. 3c), demonstrating that MLL-AF4 is required
for expression of PROM1. MLL-AF4 knockdown also
reduced the expression of TAPT1, consistent with the idea
that the two genes are co-regulated by MLL-AF4 (p <
0.001, Fig. 2d and Supplementary Fig. 3b, c). Taken toge-
ther, these data demonstrate that PROM1 is directly bound
and transcriptionally regulated by MLL-AF4 in CD133+
MLL-AF4 ALL.
Fig. 1 CD133 expression is essential for MLL-AF4 ALL cell
growth. a Flow cytometry data showing CD133+ expression in dif-
ferent leukemia cell lines. Representative of two biological replicates.
b Flow cytometry data showing the percentage of CD133+ cells in
blast populations from 12 MLLr and 32 non-MLLr infant and child-
hood ALL patients. Box represents median and interquartile range;
whiskers show minimum and maximum values, ****p < 0.0001. Mean
values: 64.9% ± 10.2 s.e.m. and 15.7% ± 4.2 s.e.m.; median: 74.9%
and 2.5% for MLLr and non-MLLr blasts, respectively. c Expression
of PROM1 by RNA-seq from two independent published datasets Left:
expression of PROM1 in MLL-AF4 ALL patients compared with non-
MLLr ALL patient blasts from Ref. [32], ***p < 0.001; right:
expression of PROM1 in MLLr ALL patients compared with non-
MLLr ALL patient blasts from Ref. [33], *p < 0.05. d qRT-PCR of
PROM1 in untreated control (black) and doxycycline-treated (orange)
PROM1 shRNA 1 SEM cells after 24, 48, and 72 h. Error bars
represent s.e.m. of three biological replicates, ***p < 0.001, **p <
0.01, ns= no significant difference. e Flow cytometry analysis
showing CD133 level in PROM1 shRNA 1 SEM cell line in control
(black) and induced (orange) conditions at day 1 (24 h doxycycline
treatment) and day 17 (following colony assay). Histograms are
representative of three replicates. f Colony assay showing percentage
of colonies formed in control and PROM1 shRNA 1 and 2 SEM cell
lines in the presence of 0.5 µg/ml doxycycline (+Dox) compared with
uninduced control (Con=−Dox). Error bars represent s.d. of three
(control) or four (shRNA) biological replicates, **p < 0.01, ns= no
significant difference. g Growth curve showing cumulative cell num-
ber for control (circles) and PROM1 shRNA 1 (triangles) and 2
(squares) SEM cell lines grown in the presence (+Dox, orange) or
absence (Con, black) of 0.5 µg/ml doxycycline. Cells were split into
fresh medium every 3 days. Error bars represent s.e.m. of three bio-
logical replicates. h Cell cycle analysis using flow cytometry in control
(black) and 72 h post induction (+Dox, orange) of PROM1 shRNA 1
cell line. Error bars represent s.e.m. from three biological replicates,
***p < 0.001, **p < 0.01, ns= no significant difference. i MA plot
showing differentially expressed genes from RNA-seq 72 h post
induction of PROM1 shRNA 1. Statistically significant differences
(865 upregulated: red; 1147 downregulated: blue; and 10,385
unchanged: black) from three biological replicates, FDR < 0.05. j
KEGG analysis of significantly downregulated genes from RNA-seq
analysis, displaying ten most enriched processes.







































































































































































Fig. 2 MLL-AF4 regulates PROM1 via H3K79me2/3. aMLL-N and
AF4-C ChIP-seq in SEM, RS4;11, MLL-AF4 ALL primograft, and
FLAG-tagged MLL-Af4 cell line at PROM1 and TAPT1. Location of
primers used for ChIP-qPCR is indicated below the traces. b
H3K79me2/3 ChIP-seq at PROM1 and TAPT1 in SEM, RS4;11, and
primograft cells. cMLL-N and AF4-C ChIP-qPCR in control (red) and
MLL-AF4 siRNA knockdown (pink) SEM cells at a negative control
locus (CON), BCL11A and several regions of PROM1 and TAPT1 in
SEM cells (primer locations indicated in a). Error bars represent s.e.m.
from five biological replicates. d Nascent RNA-seq from control
(black) and MLL-AF4 siRNA knockdown (orange) SEM cells at
PROM1 and TAPT1. e H3K79me2 and H3K79me3 ChIP-qPCR in
control (dark shade) and MLL-AF4 siRNA knockdown (light shade)
SEM cells at a negative control locus (CON), BCL11A and several
regions of PROM1 and TAPT1 in SEM cells (primer locations indi-
cated in a). Error bars represent s.e.m. from five biological replicates. f
Reference-normalized H3K79me3 [18, 58] ChIP-seq and nascent
RNA-seq in control (DMSO; dark purple/black) and EPZ-5676-treated
(DOT1Li; light purple/orange) SEM cells at PROM1 and TAPT1. g
Flow cytometry analysis of CD133 level in SEM cells following
control (DMSO; black) or EPZ-5676 treatment (DOT1Li; orange).
Representative of two biological replicates.
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MLL-AF4 controls PROM1 expression via
H3K79me2/3
We and others have shown that a common mechanism of
MLL-AF4 gene activation is via aberrant recruitment of
DOT1L leading to high levels of H3K79me2/3 [16, 17]. To
test whether MLL-AF4 directs DOT1L activity at PROM1
we performed DOT1L and H3K79me2/3 ChIP-qPCR in
SEM cells following MLL-AF4 knockdown. We observed a
reduction in both DOT1L and H3K79me2/3 at PROM1 and
TAPT1, as well as BCL11A (Fig. 2e and Supplementary
Fig. 3d). This indicates that MLL-AF4 may control PROM1
and TAPT1 transcription via H3K79me2/3.
To test this we used the DOT1L-specific small molecule
inhibitor EPZ-5676 (DOT1Li) to deplete levels of H3K79
methylation, with a near-complete loss of H3K79me3 at
PROM1 and TAPT1 (Fig. 2f). Expression of both PROM1
and TAPT1 was sensitive to DOT1Li, with nascent RNA-
seq [17, 18] and qRT-PCR demonstrating a significant
decrease in transcription, comparable to the downregulation
observed following MLL-AF4 knockdown (Fig. 2f and
Supplementary Fig. 3b, c). Levels of cell surface CD133
were similarly reduced following DOT1Li (Fig. 2g). Taken
together these data suggest that MLL-AF4 controls PROM1
expression via deposition of H3K79me2/3.
PROM1 is regulated by H3K79me2/3 enhancers
To further understand the regulation of PROM1 by MLL-
AF4 we explored the chromatin landscape at PROM1 by
ChIP-seq and ATAC-seq in SEM and RS4;11 cells and
primary blast cells from an MLL-AF4 ALL patient, which
we confirmed were CD133-positive (Supplementary
Fig. 1e, upper panels). Strikingly, in both cell lines (Fig. 3a)
and the primary blasts (Fig. 3b) we observed regions
marked with H3K27ac, H3K4me1, and H3K79me2/3 and
peaks of accessibility within the gene body of PROM1 and
TAPT1, indicative of intragenic enhancers (highlighted
regions). We have recently demonstrated that KEEs can be
functionally important [18] and so we hypothesized that
these KEEs may be a common mechanism to upregulate
PROM1 and TAPT1 in MLL-AF4 ALL.
One characteristic of an active enhancer is that it phy-
sically contacts the promoter of the gene it regulates [42–
45]. To test whether this was true for these putative
enhancers, we performed next generation Capture-C to
identify regions interacting with the promoters of PROM1
and TAPT1. In both SEM and RS4;11 cells, the PROM1 and
TAPT1 KEEs were found in close proximity with their gene
promoter, demonstrated by a peak in interaction frequency
over the enhancers (Fig. 3a). Interestingly, these interactions
were reciprocal, with the PROM1 intragenic enhancer also
contacting the TAPT1 promoter, and vice versa (Fig. 3a).
This strongly argues that these genes exist within the same
regulatory domain in SEM and RS4;11 cells, with a
potential clover leaf structure whereby both promoters and
enhancers may be in close proximity at the same time
(Fig. 3c), consistent with their correlated expression in
leukemia.
As H3K27ac is commonly used as a marker of active
enhancers, a reduction in H3K27ac may be indicative of
reduced enhancer activity. We have previously demon-
strated that DOT1Li in SEM cells results in a loss of
H3K27ac at KEEs [18]. Indeed, there was a striking
reduction in H3K27ac at the KEEs of PROM1 and TAPT1
following loss of H3K79me2/3 (Fig. 3d). We observed a
similar effect by H3K27ac ChIP-qPCR in both SEM and
RS4;11 cells (Supplementary Fig. 3e, f). Notably, MLL-
AF4 siRNA knockdown produced a similar reduction in
H3K27ac (Supplementary Fig. 3g), further suggesting that
upregulation of TAPT1 and PROM1 by MLL-AF4 is
achieved via KEE enhancer function. DOT1Li also led to a
reduction in chromatin accessibility at the KEEs of both
PROM1 and TAPT1 in SEM and RS4;11 cells [18] (Fig. 3d,
e) indicative of a reduction in transcription factor binding.
We have previously shown that interactions between
KEEs and gene promoters are disrupted by DOT1Li, con-
sistent with a loss of enhancer function [18]. Given that the
PROM1 and TAPT1 KEEs contact both gene promoters
(Fig. 3a), we asked whether these interactions were
dependent on H3K79me2/3. To test this, we performed
Capture-C following DOT1Li in SEM and RS4;11 cells.
Strikingly, we observed clear reductions in the interactions
between the PROM1 promoter and the KEEs within both
PROM1 and TAPT1 in SEM (Fig. 4a) and RS4;11 cells
(Fig. 4b). A statistical analysis of enhancer–promoter con-
tact frequency confirmed significant decreases in interaction
between the KEEs in PROM1 and TAPT1 and both pro-
moters (Fig. 4c, d), arguing that H3K79me2/3 is necessary
for enhancer function. Given the decreased expression of
PROM1 following DOT1Li or MLL-AF4 knockdown, this
suggests that the loss of enhancer–promoter interactions in
the absence of H3K79me2/3 may in part be responsible for
the reduction in PROM1 transcription and subsequent loss
of cell surface CD133.
PROM1 is polycomb-repressed in CD133− acute
leukemia
As observed, not all MLLr leukemias are CD133+ (Fig. 1a,
b), and the mechanism of differential PROM1 regulation in
leukemia is unknown. To investigate this, we analyzed
THP1 cells, an MLL-AF9 AML cell line that does not
express PROM1/CD133 (Fig. 1a and Supplementary
Fig. 1a). In contrast to SEM cells, we observed no peak of
MLL-N (which detects both MLL-AF9 and wild-type
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MLL) at PROM1 in THP1 cells or histone modifications
associated with enhancers (H3K4me1, H3K27ac, and
H3K79me2/3) or promoters (H3K4me3 and H3K27ac)
(Fig. 5a). We have previously shown that MLL-AF9 acti-
vates target gene expression in THP1 cells by a similar
mechanism to MLL-AF4 in SEM cells [17], so we asked
why it is unable to bind or activate PROM1. Deposition of
H3K27me3 by EZH2, the enzymatic component of PRC2,
is one mechanism by which genes can be silenced, and is
often targeted to developmentally regulated genes [46].
Strikingly, a peak of H3K27me3 and EZH2 was visible at
the PROM1 promoter in place of a strong H3K4me3 peak,
whereas no enrichment for H3K27me3 was observed in
SEM cells (Fig. 5a, bottom panels). Indeed, we were able to
partially relieve the repression of PROM1 by treatment of
THP1 cells with the EZH1/2 and EZH2-specific inhibitors
UNC1999 and GSK126, respectively (Supplementary
Fig. 4a). These results suggest that PROM1 repression in
THP1 cells is associated with PRC2-mediated H3K27me3,
explaining the absence of CD133 on the cell surface.
Interestingly, TAPT1, unlike PROM1, is expressed in






































































































−125000−100000 −75000 −50000 −25000 0





−80000 −60000 −40000 −20000 0













−80000 −60000 −40000 −20000 0




−125000 −100000 −75000 −50000 −25000 0










































* * * **
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Fig. 3 PROM1 is regulated by H3K79me2/3-marked enhancers. a
Capture-C tracks from the viewpoint (gray bars) of the PROM1 and
TAPT1 promoter in SEM and RS4;11 cells. ChIP-seq tracks for MLL-
N, H3K79me3, H3K27ac, H3K4me1, and H3K4me3, and ATAC-seq
at PROM1 and TAPT1 in SEM cells, and for MLL-N, H3K79me2,
H3K27ac, and H3K4me1, and ATAC-seq at PROM1 and TAPT1 in
RS4;11 cells. Putative enhancer regions are highlighted in blue. b
H3K79me3, H3K27ac, H3K4me1 and H3K4me3 ChIP-seq, and
ATAC-seq from bone marrow of a child with MLL-AF4 ALL. CD133
expression profile of these cells is shown in Supplementary Fig. 1e
(upper panels). Putative enhancer regions are highlighted in blue. c
Model for the structure of the PROM1/TAPT1 locus, based on
Capture-C data. d ATAC-seq and H3K27ac ChIP-seq at PROM1 and
TAPT1 in control (DMSO; orange/green) and EPZ-5676-treated
(DOT1Li; gray) SEM cells. Statistically significant decreases in
ATAC-seq peaks following DOT1Li are indicated by blue asterisks
(FDR < 0.05 from three biological replicates). Histograms show
overlay of ATAC-seq and H3K27ac ChIP-seq read counts across the
highlighted regions. e ATAC-seq in control (DMSO; orange) and
EPZ-5676-treated (DOT1Li; gray) RS4;11 cells. Histograms represent
overlay of ATAC-seq read counts across the highlighted regions.
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bound by MLL-AF9 and marked with active chromatin
features (Fig. 5a). In contrast to PROM1-expressing SEM
and RS4;11 cells (Fig. 3a), however, spreading of the MLL-
FP and H3K79me2/3 into the gene body appears to be
diminished, associated with reduced H3K27ac (Fig. 5a).
This lack of a strong KEE region may in part explain the
reduced expression of TAPT1 in THP1 cells (Supplemen-
tary Fig. 1a).
To assess whether PRC2 silencing is a common
mechanism for PROM1 regulation in CD133-negative leu-
kemia and not restricted to MLL-AF9 AML, we analyzed
RCH-ACV (non-MLLr Pre-B-ALL) and ML-2 (MLL-AF6
AML) cell lines, which do not express PROM1 or present
CD133 on the cell surface (Fig. 1a and Supplementary
Fig. 1a). We observed a peak of H3K27me3 at the promoter
of PROM1 in both RCH-ACV and ML-2 cells (Fig. 5b and
Supplementary Fig. 4b), colocalizing with EZH2 in RCH-
ACV cells (Fig. 5b and Supplementary Fig. 4c), indicating
that this may be a common mechanism to repress PROM1
in CD133− AML and ALL cells. We also observed no
binding of MLL-N at the PROM1 promoter or gene
body in MV4;11, SHI-1, and CCRF-CEM cells (Supple-
mentary Fig. 4d), but detected EZH2 at the promoter in the
latter two cell lines (Supplementary Fig. 4c), consistent
with a lack of PROM1 expression in these cells (Supple-
mentary Fig. 1a) due to PRC2 repression. From these
data we conclude that the presence of an MLL-FP or EZH2/
H3K27me3 at the PROM1 promoter may determine
whether it is expressed in leukemia cells. The reason why
PROM1 is PRC2 repressed in some cell types and expressed
in others, and whether the same mechanism drives
repression in CD133− primary ALL patient samples is
unknown, but may reflect the developmental stage of the
cell of origin in different leukemias. However, PROM1
repression does not reflect the relative expression of MLL
(KMT2A) and EZH2, as we observed no correlation between
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Fig. 4 H3K79me2/3 regulates enhancer–promoter interactions at
PROM1 and TAPT1. a, b Capture-C from the PROM1 and TAPT1
promoter (gray bars) in control (DMSO; black) and EPZ-5676-treated
(DOT1Li; orange) SEM and RS4;11 cells. Differential tracks show the
change in Capture-C signal (black: increases; red: decreases). Repre-
sentative of three biological replicates. ChIP-seq tracks for
H3K79me2/3, H3K27ac, and H3K4me1, and ATAC-seq in SEM and
RS4;11 cells. c, d Statistical analysis of Capture-C-measured changes
in interactions between PROM1 and TAPT1 promoters and enhancers
in SEM (c) and RS4;11 (d) cells, from three biological replicates. Each
circle represents a KEE (H3K79me2/3-marked enhancer element;
purple) or non-KEE (enhancer not marked with H3K79me2/3, gray).
Size of circle is inversely proportional to the significance of the change
in interaction.
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PROM1/TAPT1 H3K79me2/3 enhancers are inactive
in CD133− leukemia
As PROM1 is repressed in THP1 cells but TAPT1 is still
active we wanted to understand how the topological struc-
ture of the locus compared with SEM and RS4;11 cells,
where both genes are active and promoter–enhancer inter-
actions are prevalent (Fig. 3a, c). The absence of active
KEE marks such as H3K79me2/3, H3K4me1, and
H3K27ac, and accessible chromatin at PROM1 in
THP1 cells (Fig. 5a) is consistent with the absence of
enhancer activity, so this region would not be expected to
interact with the PROM1 and TAPT1 promoters. Indeed,
using Capture-C we observed no enrichment for interactions
between the PROM1 promoter and the intragenic PROM1
or TAPT1 KEEs, in contrast to the high frequency of con-
tacts in SEM cells (Fig. 5c). The low frequency interactions
observed spreading from the PROM1 promoter in
THP1 cells are likely due to nonspecific contacts driven by
sequence proximity, something that is often observed in
Capture-C experiments at inactive loci [21]. A similar effect
was observed for interactions with the TAPT1 promoter,
despite the fact that this gene is active (Fig. 5c). The lack of
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Fig. 5 PROM1 is polycomb-repressed in CD133− leukemia cells. a
MLL-N, H3K79me2, H3K79me3, H3K27ac, H3K4me1, H3K4me3,
H3K27me3 and EZH2 ChIP-seq, and ATAC-seq at PROM1 and
TAPT1 in THP1 cells. H3K27me3 ChIP-seq at PROM1 and TAPT1 in
SEM cells. b MLL-N, H3K27me3, and EZH2 ChIP-seq at PROM1
and TAPT1 in RCH-ACV cells. c Comparison of Capture-C tracks
from the promoter of PROM1 and TAPT1 in SEM (black) and THP1
(red) cells. Gray bars show the Capture-C viewpoint. Tracks are the
mean of three biological replicates. d Capture-C from the PROM1 and
TAPT1 promoter in control (DMSO; black) and EPZ-5676-treated
(DOT1Li; orange) THP1 cells. Differential tracks show the change in
Capture-C signal (black: increases; red: decreases). Tracks represent
the mean of three biological replicates. e Model for coregulation of
PROM1 and TAPT1 expression. Left: in CD133-positive MLLr cells,
the MLL fusion protein (MLL-FP) binds at the promoters of PROM1
and TAPT1 and spreads into the gene body. Recruitment of DOT1L
results in elevated H3K79me2/3 levels, facilitating enhancer activity.
These KEEs come into proximity with the promoters of both genes,
upregulating expression of PROM1 and TAPT1. Right: in CD133-
negative MLLr cells, PRC2 binding at the promoter of PROM1 gen-
erates a localized peak of H3K27me3 and disrupts MLL-FP binding at
the promoter and gene body, repressing PROM1 expression. MLL-FP
is still able to bind at the promoter of TAPT1, but for unknown reasons
does not spread into the gene body. The lack of MLL-FP spreading
within PROM1 and TAPT1 prevents the formation of KEEs, so the
expression of neither gene is upregulated.
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expression of TAPT1 in THP1 relative to SEM and
RS4;11 cells (Supplementary Fig. 1a). Whilst DOT1Li
treatment resulted in some decreases in promoter contacts
with local DNA sequences (Fig. 5d), there were no sig-
nificant effects on interactions with enhancer regions
(Supplementary Fig. 4f), further demonstrating the lack of
KEE behavior at this locus in THP1 cells. Taken together,
these data suggest that PRC2 inactivation of PROM1 ren-
ders the enhancers found within PROM1 inactive, poten-
tially due to the inability of MLL-FP to bind, which
consequently prevents H3K79me2/3 deposition and tran-
scription factor binding. Inactivation of PROM1 also dis-
rupts any interactions between PROM1 and the TAPT1
KEEs (and vice versa), suggesting that inactivation of
PROM1 via PRC2 repression impacts the chromatin struc-
ture and activity of the entire domain.
MLL and PRC2 regulate PROM1/CD133 expression
during lymphopoiesis
Finally, we sought to test whether the antagonistic rela-
tionship between MLL and PRC2 is associated with
PROM1/CD133 regulation in normal B cell development.
We measured CD133 levels on normal fetal BM cells by
flow cytometry (Supplementary Fig. 5a). As noted in nor-
mal cord blood and postnatal BM [6], CD133 was expres-
sed by the majority of early fetal HSPCs but was
significantly reduced on committed B progenitors (CD34+
CD19+CD10− PreProB and CD34+CD19+CD10+ ProB
progenitors) and almost undetectable on CD34−CD19+ B
cells (Supplementary Fig. 5a). Consistent with this, pub-
lished single-cell RT-qPCR [36] and RNA-seq [34–36] data
of normal fetal and adult BM cells demonstrated a restric-
tion of PROM1 expression to immature CD34+ stem/pro-
genitor cells (Supplementary Fig. 5b, c). Indeed, human cell
Atlas single-cell RNA-seq of adult BM cells [38] con-
firmed restriction of PROM1 expression to CD34+ cells
(Supplementary Fig. 5d). This loss of expression is
reflected by the chromatin structure at the PROM1 locus,
where ATAC-seq [34, 36] revealed peaks of accessibility
comparable to CD133+ SEM cells in stem and progenitor,
but not mature, cells from both fetal and adult BM (Sup-
plementary Fig. 5e).
To ask whether wild-type MLL had a role in PROM1
expression in HSPCs, we purified CD34+ (CD133+;
Supplementary Fig. 5a) and CD34− (CD133−) fetal BM
cells and analyzed MLL binding by ChIP-qPCR (Supple-
mentary Fig. 5f). Indeed, MLL binding was only detected at
the PROM1 promoter in the CD34+ cells and not CD34−
(CD133−) cells, whilst TAPT1 and CDK6 were bound in
both progenitor and mature populations (Supplementary
Fig. 5f). We confirmed these binding patterns in CD34+
and CD34− fetal liver (FL) cells (Supplementary Fig. 5f).
Finally, as in the CD133-negative leukemia cells (Fig. 5a,
b), the PROM1 promoter was marked by H3K27me3 in
CD34− FBM and FL, consistent with its repression by
PRC2 (Supplementary Fig. 5g). However, in adult BM
cells, as for leukemic blasts (Supplementary Fig. 4d), there
was no obvious correlation between the expression of MLL
(KMT2A), EZH2, and PROM1 (Supplementary Fig. 5d),
suggesting that PROM1 status is not simply a product of the
relative levels of the two proteins.
Discussion
We demonstrate here that MLL-AF4 directly regulates
PROM1 leading to high expression of CD133 in a major
subset of MLLr ALL patients, especially MLL-AF4 and
MLL-ENL. MLL-AF4 drives transcriptional upregulation
of PROM1 via H3K79me2/3, which in turn promotes
enhancer function. Thus, this mechanism is most likely via
aberrant recruitment of DOT1L, resulting in increased
H3K79me2/3 levels and increased enhancer–promoter
interactions (Fig. 5e), although it is probable that elevated
H3K79me2/3 also acts in part by promoting transcription
elongation. Interestingly, MLL-AF4 appears to co-regulate
high level expression of the neighboring gene TAPT1 along
with PROM1. When both genes are expressed, the PROM1
and TAPT1 KEEs interact with each other and with both
promoters in an H3K79me2/3-dependent manner. Although
TAPT1 is expressed in the absence of PROM1 transcription,
its promoter does not interact with the PROM1 KEEs, likely
driving the lower levels of expression of the TAPT1 gene
(Fig. 5e). Consistent with this, we observe a correlation
between expression of PROM1 and high levels of expres-
sion of TAPT1 in ALL patient samples (Supplementary
Fig. 1c). This correlation is not observed in normal hema-
topoietic cells (Supplementary Fig. 5c, d), consistent with
the idea that it is dependent on the MLL-FP-
generated KEEs.
One question which arises from our work is why CD133
is expressed in some MLLr leukemias and not others. It is
possible that this simply reflects the initial CD133 status of
the cell of origin, as many stem and early progenitor cells
are known to express CD133 while later progenitor and
more mature B cells do not [36, 40, 47, 48]. Another pos-
sibility is that the MLL-FP itself has the ability to bind and
cause aberrant upregulation of PROM1. Indeed, the obser-
vation that not all MLL-FPs are associated with high levels
of CD133 suggests that the activity of the fusion partner
may be important for its ability to bind at PROM1. We note
that we do not observe binding of wild-type MLL at
PROM1 in CD133− cells (Fig. 5a, b and Supplementary
Figs. 4d, 5f). Alternatively, differences in the chromatin
state at PROM1 may render the environment permissive for
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MLL-FP spreading only in certain target cell types, so
leukemias that initiate in a PROM1-repressed environment
may not be capable of reactivating the locus. For instance,
in CD133− leukemia cell lines such as THP1 and RCH-
ACV, the promoter of PROM1 is bound by EZH2 (the
enzymatic component of PRC2) and marked with
H3K27me3, suggesting that the gene is polycomb-
repressed.
What determines whether MLL-FP or PRC2 becomes
stably bound at PROM1? Polycomb and Trithorax group
proteins (such as MLL) are known to be antagonistic [49],
so stable PRC2 binding at the promoter may prevent MLL-
FP association, and vice versa (both can recognize unme-
thylated CpG islands [49]). In this model, in CD133−
leukemias PRC2 wins this competition, rendering PROM1
repressed. In contrast, in MLLr CD133+ leukemias MLL-
FP binding may be preferentially stabilized over PRC2
and therefore PROM1 is activated. In past work, we have
noted that the spreading of MLL-AF4 binding into the
gene body, as observed at PROM1, is associated with par-
ticularly high levels of MLL-AF4-mediated transcription
[17], but it was not known whether spreading initiated at the
promoter. The fact that when PROM1 is repressed the
MLL-FP is also absent from the body of the gene (even
though PRC2 is not bound here) suggests that spreading
may nucleate from the promoter. It should be noted that
non-MLLr leukemias can also be CD133+ (see Fig. 1b and
[40, 50, 51]), as are many stem cells [36, 40], in the absence
of an MLL-FP to drive expression. We identified MLL
binding at the PROM1 promoter in normal fetal CD34+
stem and progenitor cells (Supplementary Fig. 5f), arguing
that wild-type MLL plays a role in PROM1 expression, and
there are likely other oncogenic mechanisms for PROM1
upregulation.
Our work here suggests that early stem/progenitor cell
expression of PROM1/CD133 eventually becomes repres-
sed by PRC2 in more mature cells. This raises an important
question—do MLL-FPs such as MLL-AF4 overcome this
repressive environment and aberrantly activate PROM1/
CD133 or does the transformation event occur in a pro-
genitor cell that still displays PROM1/CD133 expression?
Our data cannot fully answer this question, but an emerging
model in the field suggests that PRCs are responsive to,
rather than instructive for, gene repression [49, 52, 53].
What this might indicate is that PROM1/CD133 is normally
repressed by various developmental signals (e.g., binding of
repressive transcription factors) that eventually lead to PRC-
mediated repression. If MLL-FPs are able to bind to
PROM1 in a cell type that has not completely repressed the
locus, this could lead to a disruption of the normal repres-
sive machinery and reactivation of the gene. The fact that
inhibiting PRC2 activity partially reactivates the locus
(Supplementary Fig. 4a) suggests that, even in CD133−
cells, there is some low-level ability to activate the locus
that is normally suppressed.
The mechanism of PROM1 regulation is of relevance
when considering the fetal cell of origin of infant MLL-AF4
ALL, which invariably originates in utero. CD133 is
expressed during normal fetal hematopoiesis primarily in
hematopoietic stem cells (HSCs) and early progenitors
(multipotent progenitors (MPPs) and lymphoid-primed
MPPs) [36, 40]. This is consistent with a permissive
environment for MLL-AF4 binding at PROM1, if the leu-
kemia was initiated in any of these cell types. However,
infant MLL-AF4 ALL shares some characteristics with a
more developed B cell progenitor [20] such as fetal BM
PreProB progenitors [36], suggesting this could be the cell
of origin [33, 54]. In these cells PROM1 is much more
weakly expressed and may be in the process of PRC2
repression, but MLL-AF4 induction could antagonize this
process by competing for binding at the promoter. Notably,
the chromatin environment at PROM1 remains accessible in
PreProB progenitor cells, despite the low expression level,
and therefore may be permissive for MLL-AF4 binding.
Thus, the balance between Trithorax and polycomb group
proteins at PROM1 upon leukemia initiation may render
CD133 either highly expressed or absent.
One important question is whether CD133 could be a
useful therapeutic target. Since CD133 is expressed on both
fetal and adult HSCs, it may be difficult to target CD133+
blasts without impacting normal HSCs [40]. One approach
that has been proposed is to combine CD133 targeting with
a second marker found on ALL blasts such as CD19 [4]. An
“AND gate” strategy that requires dual target engagement
for activity would spare normal HSCs. However, such a
strategy is contingent on the inability of the leukemia cells
to downregulate expression of either marker. Of note, we
show here that continuous expression of CD133 is essential
for the growth of SEM and RS4;11 cells, as it functions
at least in part by promoting cell cycle progression and
suppressing apoptosis. This suggests that CD133+ leuke-
mia cells may be addicted to CD133 expression
(whilst CD133− blasts tolerate its absence). However, some
long-term repopulating ALL cells have been shown to be
CD133+/CD19−, complicating the use of an “AND gate”
strategy in this way [51]. In the large subset of MLLr ALL
patients where PROM1/CD133 is co-expressed with CD19,
CD133/CD19 dual AND gate targeting could be a pro-
mising targeted therapeutic approach in difficult-to-treat
infants, children, and adults. To be truly effective in a wide
range of patients, combination therapy will be required,
with other approaches such as BCL2 inhibition [55, 56] or
targeting other MLLr-specific cell surface receptors, such as
NG2 [57].
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Data availability
All high-throughput data have been deposited in the Gene
Expression Omnibus (GEO) under accession number
GSE135026. Accession numbers for datasets used from
previous publications can be found in Supplementary
Table 3.
Code availability
The ChIP-seq and ATAC-seq sequence mapping pipeline
can be accessed at https://github.com/Hughes-Genome-
Group/NGseqBasic/releases. Capture-C analysis code is
available from https://github.com/Hughes-Genome-Group/
CCseqBasicF/releases.
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